qing
mao
phone
abstract
excess
immun
respons
contribut
sarscov
merscov
pathogenesi
lethal
mechan
remain
unclear
studi
n
protein
sarscov
merscov
found
bind
key
serin
proteas
lectin
pathway
complement
activ
result
aberr
complement
activ
aggrav
inflammatori
lung
injuri
either
block
n
protein
interact
suppress
complement
activ
significantli
allevi
n
proteininduc
complement
hyperactiv
lung
injuri
vitro
vivo
complement
hyperactiv
also
observ
patient
promis
suppress
effect
observ
deterior
patient
treat
monoclon
antibodi
complement
suppress
may
repres
common
therapeut
approach
pneumonia
induc
highli
pathogen
coronavirus
short
titl
sarscov
n
overactiv
complement
one
sentenc
summari
lectin
pathway
complement
activ
promis
target
treatment
highli
pathogen
coronaviru
induc
pneumonia
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
medrxiv
preprint
previous
demonstr
sarscov
n
protein
interact
number
host
protein
includ
altern
splice
product
thu
studi
interact
sarscov
merscov
n
protein
intens
investig
patholog
effect
interact
host
immun
inflamm
also
elucid
provid
mechan
support
immunomodulationbas
therapi
current
epidem
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
sever
acut
respiratori
syndrom
sar
initi
report
guangdong
china
novemb
highli
contagi
deadli
respiratori
diseas
sever
acut
respiratori
syndrom
coronaviru
sarscov
identifi
novel
etiolog
agent
diseas
nearli
decad
sar
outbreak
new
zoonot
coronaviru
middl
east
respiratori
syndrom
mer
coronaviru
merscov
identifi
etiolog
agent
mer
recent
new
coronaviru
first
identifi
wuhan
china
spread
rapidli
provinc
china
world
march
infect
peopl
fatal
rate
http
infect
viru
caus
sever
atyp
pneumonia
similar
sarscov
infect
although
pathogenesi
diseas
intens
investig
still
well
understood
viral
infect
lead
respiratori
failur
high
fatal
rate
sarscov
nucleocapsid
n
protein
viral
rnabind
protein
share
homolog
n
protein
known
coronavirus
wherea
n
protein
highli
pathogen
coronavirus
similar
includ
merscov
blastp
n
protein
one
abund
viral
structur
protein
patient
sera
sarscov
infect
potenti
n
protein
play
role
viru
pathogenesi
preadministr
n
protein
viral
protein
via
recombin
vaccinia
viru
venezuelan
equin
enceph
viru
replicon
particl
result
sever
pneumonia
age
mice
challeng
sarscov
complement
system
function
immun
surveil
system
rapidli
respond
infect
activ
complement
system
result
pathogen
elimin
acut
chronic
inflamm
nevertheless
dysregul
complement
activ
implic
develop
acut
lung
diseas
induc
highli
pathogen
virus
complement
system
activ
via
classic
pathway
cp
lectin
pathway
lp
altern
pathway
ap
lp
mannanbind
lectin
mbl
ficolin
bind
carbohydr
array
mannan
nacetylglucosamin
residu
surfac
virus
surfac
virusinfect
cell
result
activ
mblassoci
serin
known
mblassoci
proteas
directli
initi
complement
cascad
mbl
bind
sarscovinfect
cell
dosedepend
calciumdepend
mannaninhibit
manner
vitro
enhanc
deposit
complement
sarscov
nlink
glycosyl
site
sarscov
spike
protein
critic
specif
interact
mbl
although
higher
level
activ
complement
fragment
found
sar
patient
indic
activ
complement
pathway
mechan
sarscovinduc
complement
activ
well
understood
also
unknown
whether
similar
pathogenesi
occur
infect
investig
bind
n
protein
sarscov
delin
interact
domain
two
protein
lysat
human
cell
express
flagtag
fulllength
ntermin
region
ctermin
region
fig
subject
antiflag
immunoprecipit
use
antiflag
antibodyconjug
agaros
bead
immunoprecipit
next
incub
cell
lysat
express
gfptag
sarscov
n
protein
gfpsar
n
truncat
mutant
presenc
mm
cacl
mm
edta
adsorb
probe
antiflag
antigfp
antibodi
immunoblot
associ
gfp
sar
n
observ
presenc
cacl
fig
agreement
requir
ca
bind
autoactiv
region
fig
ntermin
domain
residu
n
protein
fig
fig
crucial
associ
wherea
neg
control
truncat
region
bind
gfptag
fulllength
truncat
n
protein
co
immunoprecipit
mous
igg
conjug
bead
fig
fig
sarscov
n
protein
detect
patient
serum
earli
day
onset
symptom
simul
sarscov
n
protein
associ
serum
flagtag
n
protein
ngml
ad
human
mous
serum
precipit
antiflag
antibodi
conjug
agaros
bead
sarscov
n
protein
interact
deriv
human
mous
serum
fig
truncat
delet
analysi
show
amino
acid
residu
locat
coil
motif
sarscov
n
protein
residu
indispens
interact
fig
howev
associ
sarscov
mutant
fail
form
n
protein
dimer
fig
much
affect
fig
crucial
motif
sarscov
n
protein
interact
residu
share
high
ident
correspond
motif
n
merscov
n
fig
suggest
n
protein
merscov
also
interact
expect
exogen
express
merscov
n
n
associ
fig
delet
mutant
mer
cov
n
exhibit
predict
reduc
associ
fig
therefor
common
motif
across
coronaviru
n
protein
import
bind
domain
respons
selfactiv
substrat
bind
activ
turn
mediat
complement
lectin
pathway
activ
n
protein
associ
demonstr
suggest
sarscov
n
protein
may
regul
dimer
activ
cleavag
demonstr
dimer
bead
incub
lysat
cell
express
presenceabs
n
protein
mbl
bind
residu
result
autoactiv
produc
presenc
sarscov
n
protein
fig
investig
effect
sarscov
n
protein
mblbind
capabl
purifi
mbl
incub
mannanco
micropl
well
avoid
activ
dynam
mbl
bind
assess
use
antibodi
compar
human
serum
albumin
hsa
highconcentr
compon
bind
buffer
use
neg
control
n
protein
bind
mbl
significantli
enhanc
presenc
sarscov
n
protein
rel
low
concentr
ca
potenti
effect
abrog
antin
protein
antibodi
fig
moreov
sarscov
n
protein
bear
delet
n
protein
less
pathogen
human
coronaviru
show
littl
effect
mbl
bind
compar
fulllength
sarscov
n
protein
fig
result
indic
sarscov
n
proteinpotenti
activ
depend
associ
also
n
protein
dimer
cleav
complement
compon
gener
convertas
lectin
pathway
complement
system
upon
activ
next
effect
sarscov
n
protein
lp
complement
activ
assess
cleavag
purifi
incub
mannan
mbl
presenceabs
equal
molar
n
protein
cleavag
observ
significantli
potenti
sarscov
n
protein
presenc
mannan
mbl
fig
fig
accordingli
mutant
sarscov
n
protein
well
n
protein
fail
promot
hydrolysi
fig
fig
notabl
monoclon
antibodi
inhibitor
block
sarscovpotenti
hydrolysi
suggest
n
proteinpotenti
cleavag
depend
activ
fig
fig
moreov
merscov
n
also
found
potenti
cleavag
fig
result
indic
n
protein
prompt
cleavag
therefor
complement
activ
associ
activ
impact
sarscov
n
protein
complement
activ
via
lectin
pathway
investig
complement
deposit
assay
purifi
incub
immobil
complex
presenc
indic
n
protein
n
protein
sarscov
merscov
n
potenti
deposit
depend
activ
dosedepend
manner
fig
immobil
mannan
incub
serum
elimin
classic
pathway
presenceabs
sarscov
n
protein
deposit
fragment
detect
antiactiv
antibodi
concert
deposit
deposit
activ
evid
increas
along
increas
sarscov
n
protein
level
nm
fig
suggest
enhanc
activ
convertas
addit
sarscov
n
protein
littl
effect
activ
deposit
calciumfre
buffer
contain
egta
suggest
sarscov
n
proteinpotenti
activ
occur
lp
ap
pathway
activ
ca
fig
shown
figur
deposit
decreas
presenc
high
concentr
n
protein
possibl
due
cleavag
solubl
inhibitor
serum
factor
h
factor
surfac
coat
high
densiti
test
deposit
complex
result
amplifi
complement
cascad
significantli
increas
deposit
complex
induc
sarscov
n
protein
much
lower
concentr
fig
similar
observ
patient
sera
activ
complement
play
crucial
role
effici
phagocytosi
pathogen
cellular
debri
opson
studi
complementdepend
phagocytosi
e
coli
mous
periton
macrophag
incub
togeth
dilut
serum
without
sarscov
n
protein
bound
larg
fragment
product
cleavag
stain
fitclabel
antibodi
fitcposit
macrophag
contain
e
coli
count
microscop
concert
complement
activ
complementdepend
phagocytosi
mice
periton
macrophag
presenc
mous
serum
contain
complement
compon
includ
enhanc
remark
sarscov
n
protein
compar
hsa
control
fig
find
indic
sarscov
n
protein
effect
promot
activ
opson
effect
complement
system
persist
activ
complement
lead
uncontrol
inflamm
investig
effect
n
proteinpotenti
activ
inflamm
mice
preinfect
adenoviru
pfu
express
sarscov
n
adsar
n
mutant
adenoviru
vehicl
adnul
mice
challeng
lp
contain
mblbind
motif
activ
lp
induc
inflamm
mice
preexpos
adenoviru
vehicl
surviv
challeng
mgkg
lp
fig
mice
preexpos
adsar
n
die
within
hr
lp
administr
dosag
fig
sever
lung
damag
massiv
inflammatori
cell
infiltr
also
observ
dead
mice
fig
concert
previou
find
preinfect
n
adsar
n
bear
delet
n
protein
respect
significantli
reduc
effect
mous
mortal
importantli
antin
antibodi
administ
simultan
lp
administr
adsar
n
preinfect
mice
death
rate
lung
tissu
inflamm
induc
lp
significantli
reduc
fig
result
collect
demonstr
sarscov
n
protein
greatli
potenti
lpsinduc
inflamm
via
activ
therebi
initi
lpinvolv
complement
cascad
activ
investig
complement
activ
lung
mice
induc
lp
n
protein
mice
preinfect
adsar
n
pfu
challeng
lp
mgkg
hr
post
lp
administr
mice
sacrif
paraformaldehydefix
lung
tissu
subject
immunohistochem
ihc
stain
antibodi
immunofluoresc
analysi
fitclabel
antibodi
activ
deposit
lung
significantli
increas
mice
express
sarscov
n
protein
fig
vivo
associ
n
protein
assess
situ
proxim
ligat
assay
pla
antin
antibodi
left
panel
fig
red
signal
detect
sarscov
n
bind
abundantli
observ
pulmonari
cell
mice
express
sarsal
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
cov
n
neg
control
anim
fig
result
confirm
situ
direct
bind
activ
sarscov
n
mice
lung
tissu
similarli
mice
challeng
lp
suffer
seriou
pneumonia
die
within
hr
preinfect
adenoviru
express
merscov
n
protein
admer
n
mutant
admer
n
day
partial
rescu
antibodi
fig
result
indic
n
protein
employ
sarscov
merscov
promot
complement
activ
lectin
pathway
pathogen
n
protein
investig
use
knockout
ko
mice
ko
region
indic
fig
proteas
activ
defici
way
mice
preinfect
adsar
n
admer
n
pfu
day
challeng
lp
compar
wildtyp
mice
ko
mice
surviv
longer
higher
surviv
rate
fig
may
attribut
compromis
complement
activ
defici
sarscov
induc
mild
lung
damag
mice
investig
live
sarscov
includ
mous
adapt
sarscov
allow
relat
regul
china
tri
get
clinic
evid
overactiv
complement
lp
pathway
occur
patient
paraformaldehydefix
lung
tissu
patient
die
collect
subject
ihc
stain
mbl
antibodi
complement
cascad
compon
demonstr
strong
ihc
stain
signal
patient
lung
tissu
fig
suggest
complement
compon
deposit
type
type
ii
alveolar
epithelia
cell
well
inflammatori
cell
hyperplast
pneumocyt
exud
alveolar
space
necrot
cell
debri
notabl
n
protein
also
observ
lung
tissu
die
patient
autopsi
significantli
increas
serum
level
also
observ
patient
particularli
sever
case
fig
result
collect
indic
complement
pathway
aggress
activ
lung
patient
may
attribut
n
protein
wide
accept
excess
inflammatori
cytokin
storm
greatli
contribut
sever
lethal
may
attribut
unrestrain
activ
complement
pathway
therefor
downregul
well
downstream
signal
molecul
potent
anaphylatoxin
may
provid
new
approach
control
pneumonia
induc
base
find
potenti
tempt
applic
therapi
recombin
antibodi
inject
staidson
beij
biopharmaceut
co
ltd
phase
clinic
trial
hidraden
suppurativa
rapidli
approv
nation
medic
product
administr
nmpa
clinic
trial
treatment
multicent
random
doubl
blind
placebocontrol
trial
mild
patient
open
label
twocohort
clinic
trial
patient
sever
critic
carri
simultan
approv
ethic
committe
huoshensan
hospit
inform
consent
patient
larger
dataset
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
patient
cohort
report
elsewher
trial
finish
report
first
case
administr
antibodi
open
label
trial
patient
year
old
male
resid
citi
wuhan
admit
dongxihu
hospit
day
onset
symptom
day
ill
fever
infect
confirm
rrtpcr
chest
ct
scan
show
bilater
opac
diseas
get
wors
day
ill
high
fever
room
air
pneumonia
progress
ct
scan
sever
hepat
damag
prednison
mgday
day
administr
day
ill
condit
deterior
patient
transfer
wuhan
huoshenshan
hospit
new
hospit
establish
urgent
sever
patient
day
ill
fig
consid
sever
case
critic
condit
moder
ard
oxygen
index
respiratori
rate
percutan
oxygen
satur
drop
expos
room
air
minut
support
care
includ
highflow
nasal
oxygen
hfno
target
fig
left
also
administr
antibiot
moxifloxacin
human
serum
albumin
prednison
discontinu
treatment
monoclon
antibodi
initi
morn
day
ill
antibodi
given
intraven
ml
salin
dosag
mgday
day
advers
event
observ
clinic
condit
improv
next
day
normal
bodi
temperatur
even
day
fig
left
increas
oxygen
index
pao
fio
fig
left
lymphocyt
cell
number
fig
left
decreas
c
reactiv
protein
crp
concentr
fig
left
significantli
improv
hepat
function
shown
decreas
alt
ast
increas
total
serum
protein
serum
albumin
concentr
fig
left
fraction
inspir
ga
flow
rate
highflow
nasal
oxygen
hfno
eventu
decreas
highest
lmin
lmin
target
fig
left
high
risk
take
patient
critic
condit
ct
scan
temporarili
establish
hospit
long
distanc
cold
rain
weather
without
hfno
ct
scan
administr
avail
evalu
nevertheless
pneumonia
day
dose
observ
obvious
improv
day
dose
fig
upper
panel
patient
year
old
male
admit
sixth
hospit
wuhan
day
onset
symptom
day
ill
fever
cough
ct
scan
show
opac
superior
lobe
left
lung
fig
infect
also
confirm
rrtpcr
day
ill
antivir
arbidol
antibiot
moxifloxacin
administr
togeth
support
treatment
condit
worsen
day
sever
cough
high
fever
fig
right
methylprednisolon
mgday
day
day
ill
show
littl
improv
symptom
patient
transfer
wuhan
huoshenshan
hospit
day
fig
ill
continu
get
wors
shown
room
air
day
high
fever
day
fig
right
pneumonia
chest
ct
day
ill
day
dose
fig
lower
panel
patient
report
sever
cough
chest
tight
dyspnea
hfno
given
maintain
administr
morn
ill
day
continu
patient
subsequ
normal
temperatur
observ
day
fig
right
cough
dyspnea
oppress
chest
report
get
better
next
day
day
ill
signific
decreas
c
reactiv
protein
crp
level
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
significantli
increas
white
blood
cell
lymphocyt
number
also
observ
next
day
fig
right
hepat
function
gradual
improv
fig
right
data
day
avail
flow
rate
fraction
inspir
necessari
maintain
gradual
decreas
increas
fig
right
chest
ct
day
ill
day
dose
also
show
allevi
pneumonia
fig
lower
panel
data
provid
first
evid
damag
role
sever
affect
patient
two
sever
patient
significantli
benefit
monoclon
antibodi
therapi
suggest
aberr
complement
cascad
consid
promis
therapeut
target
past
year
success
emerg
sarscov
merscov
broke
speci
barrier
brought
new
infecti
diseas
social
panic
human
highli
pathogen
coronaviru
caus
acut
lung
injuri
acut
respiratori
distress
syndrom
ard
therefor
result
increas
sever
lethal
patient
infect
viru
may
develop
atyp
pneumonia
result
sever
immun
injuri
excess
human
immun
respons
character
extens
releas
proinflammatori
cytokin
chemokin
call
cytokin
storm
thought
major
initi
sever
pneumonia
caus
high
pathogen
coronaviru
includ
latest
although
immunopathogenesi
partial
implic
sar
mer
mechan
respons
virusinduc
hyperactiv
host
immun
system
remain
poorli
understood
show
sarscov
merscov
share
common
mechan
connect
viral
n
protein
bind
potenti
mbl
ca
autoactiv
lead
uncontrol
activ
complement
cascad
character
enhanc
cleavag
complement
deposit
fig
bind
n
protein
amplifi
effect
lectin
pathway
activ
n
protein
mutant
either
fail
interact
fail
form
n
dimer
littl
effect
lectin
pathway
activ
fig
suggest
effect
n
protein
depend
bind
dimer
dualedg
sword
complement
critic
innat
immun
pathogen
anaphylatoxin
activ
immun
cell
therefor
induc
releas
variou
cytokin
activ
complement
cascad
produc
cytolyt
termin
complement
complex
fragment
peptid
induc
synthesi
arachidon
acid
metabolit
includ
prostaglandin
pg
thromboxan
leukotrien
induc
recruit
activ
neutrophil
monocyt
eosinophil
stimul
product
number
proinflammatori
cytokin
mediat
cytokin
trigger
maintain
inflammatori
process
help
innat
immun
fight
viru
nevertheless
complementinvolv
innat
immun
activ
must
finetun
unrestrain
complement
activ
alway
contribut
dissemin
intravascular
coagul
dic
inflamm
cell
death
immun
paralysi
ultim
lead
multipl
organ
failur
death
find
coronaviru
n
protein
potenti
complement
activ
provid
new
insight
causat
pneumonia
induc
sarscov
merscov
infect
addit
also
notic
preinfect
adsar
n
admer
n
evid
increas
fatal
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
lpsinduc
pneumonia
fig
underlin
potenti
role
n
protein
inflammatori
injuri
tissu
caus
massiv
lp
releas
secondari
bacteri
infect
involv
n
proteinmedi
therefor
complement
cascad
overactiv
pathogenesi
coronaviru
provid
new
potenti
strategi
develop
therapeut
sar
mer
latest
schemat
summari
demonstr
fig
firstli
neutral
n
protein
serum
antibodi
effect
allevi
lung
injuri
reduc
fatal
lpsadsar
n
challeng
mice
coincident
sar
patient
produc
higher
level
n
protein
specif
spike
protein
specif
antibodi
tend
recov
rapidli
suggest
level
n
antibodi
correl
outcom
sar
accord
find
similar
mechan
may
present
merscov
infect
secondli
ko
mice
show
significantli
mild
symptom
shorter
cours
diseas
lp
induc
n
protein
boost
mice
pneumonia
model
confirm
harm
role
sever
pneumonia
accordingli
administr
antibodi
inhibitor
show
promis
treatment
effect
fig
improv
antibodi
higher
affin
neutral
activ
show
promis
effect
thrombot
microangiopathi
inject
medicin
haegarda
may
provid
effect
protect
clinic
evalu
valu
carri
treatment
induc
pneumonia
thirdli
observ
excess
activ
complement
cascad
lung
tissu
dead
patient
coincid
observ
adsar
n
preinfect
lpsprime
mice
model
highlevel
accumul
serum
sever
mild
patient
fig
make
sens
complement
cascadetarget
immunomodul
may
effect
inflammationcontrol
highli
pathogen
coronavirusrel
diseas
pathway
potent
complement
protein
trigger
inflamm
blockag
signal
also
report
improv
treatment
acut
lung
injuri
ali
induc
highli
pathogen
virus
base
scientif
find
good
safeti
record
phase
ii
trial
diseas
staidson
inflarx
gmbh
produc
antibodi
cell
line
recombin
antibodi
produc
staidson
biopharmaceut
approv
nmpa
clinic
trial
treatment
sever
critic
patient
least
first
two
patient
diseas
deterior
antibodi
show
rapid
promis
effect
exceed
expect
clinic
physician
although
final
efficaci
releas
clinic
trial
finish
worth
expect
antibodi
would
provid
new
approach
treatment
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
immunoprecipit
immunoblot
cell
lysat
prepar
lysi
buffer
mm
trishcl
ph
mm
phenylmethylsulfonyl
fluorid
mm
dithiothreitol
mm
sodium
fluorid
aprotinin
leupeptin
pepstatin
contain
nonidet
solubl
protein
subject
immunoprecipit
antiflag
agaros
sigma
adsorb
separ
sdspage
transfer
onto
immobilonp
transfer
membran
millipor
semidri
transblot
biorad
membran
block
westernblock
biorad
immunoblot
analysi
perform
horseradish
peroxidas
hrp
conjug
antiflag
sigma
sigma
antigreen
fluoresc
protein
gfp
clontech
santa
cruz
santa
cruz
hrpconjug
antimyc
santa
cruz
goat
antimous
immunoglobulin
g
igg
amershampharmacia
antibodi
antigenantibodi
complex
visual
chemiluminesc
ge
health
care
describ
previous
n
transform
express
strain
induct
mm
iptg
h
bacteria
harvest
centrifug
resuspend
buffer
mm
na
hpo
nah
po
ph
mm
edta
mm
dtt
sonic
solubl
n
protein
lysat
purifi
ionexchang
chromatographi
spsepharos
fast
flow
mm
na
hpo
nah
po
ph
mm
edta
mm
dtt
nacl
follow
superdex
gel
filtrat
ge
healthcar
elut
buffer
e
coli
transform
vector
lyse
describ
eluat
use
neg
control
purifi
n
purif
renatur
recombin
protein
express
renatur
perform
describ
brief
transform
express
host
strain
induct
mm
iptg
cell
harvest
sonic
inclus
bodi
solubil
guhcl
trishcl
ph
mm
dtt
room
temperatur
solubil
protein
dilut
refold
buffer
contain
mm
trishcl
mm
reduc
glutathion
sigma
mm
oxid
glutathion
sigma
mm
edta
arginin
protein
sampl
cool
renatur
protein
dialyz
mm
tri
mm
nacl
ph
concentr
aliquot
store
obtain
highact
flagtag
express
cell
precipit
antiflag
magnet
bead
elut
flag
peptid
sigma
concentr
assess
use
bca
kit
immunoblot
analysi
purifi
prokaryoticexpress
standard
control
autoactiv
cleavag
assay
purifi
nm
incub
mm
trishcl
ph
mm
nacl
mm
cacl
purifi
calbiochem
recombin
mbl
calbiochem
mannan
sigma
sarscov
n
protein
concentr
nm
nm
ngml
nm
respect
cleavag
follow
sdspage
reduc
condit
fragment
left
releas
cleavag
indic
activ
detect
immunoblot
analysi
chain
antibodi
santa
cruz
antiflag
antibodi
sigma
contain
use
indic
band
posit
deposit
assay
perform
use
human
assay
kit
hycult
biotech
brief
dilut
serum
incub
mannanco
plate
high
salt
bind
buffer
overnight
remov
wash
complex
captur
purifi
n
protein
ad
incub
hr
deposit
detect
follow
standard
protocol
function
activ
lp
ap
assess
elisa
previous
describ
nunc
maxisorb
plate
coat
mannan
per
well
mm
na
co
nahco
ph
room
temperatur
overnight
step
plate
wash
three
time
pbst
residu
bind
site
block
incub
mm
trishcl
ph
mm
nacl
hsa
hr
room
temperatur
serum
sampl
dilut
mm
trishcl
ph
contain
mm
nacl
mm
mgcl
gelatin
without
mm
cacl
n
protein
sampl
buffer
prepar
ice
plate
sequenti
incub
hr
hr
follow
wash
incub
volum
complement
bind
detect
use
antibodi
follow
wash
detect
activ
perform
use
chain
antibodi
santa
cruz
antiactiv
antibodi
santa
cruz
antibodi
calbiochem
respect
bind
mbl
assess
elisa
mention
nunc
maxisorb
plate
coat
mannan
per
well
mm
na
co
nahco
ph
room
temperatur
overnight
block
hsa
mbl
protein
incub
mm
trishcl
ph
mm
nacl
mm
cacl
hsa
hr
purifi
n
control
protein
ad
well
differ
time
obtain
final
concentr
mgml
ngml
respect
plate
wash
hr
incub
bind
detect
antibodi
follow
hrpconjug
rabbit
antigoat
antibodi
enzym
activ
hrp
detect
use
tmb
incub
min
rt
reaction
stop
h
od
measur
nm
use
micropl
reader
mous
cell
isol
periton
caviti
wash
inocul
rpmi
media
fb
plate
hr
serum
dilut
cacl
mgcl
dilut
serum
sarscov
n
protein
e
coli
ratio
cell
ad
well
incub
minut
eluat
e
coli
use
neg
control
purifi
n
protein
exclud
effect
due
bacteri
compon
may
activ
complement
reaction
stop
cell
fix
neutral
formalin
complement
depositon
detect
antibodi
immunohistochemistri
postmortem
autopsi
patient
die
huoshenshan
hospit
carri
dr
xiuwu
bian
approv
hospit
ethic
committe
famili
member
death
detail
result
publish
elsewher
paraformaldehydefix
lung
tissu
use
paraffin
tissu
section
immunohistochem
stain
mbl
santa
cruz
santa
cruz
chain
santa
cruz
santa
cruz
calbiochem
antibodi
describ
instruct
manual
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
detect
patient
sera
mild
sever
patient
collect
approv
hospit
ethic
committe
server
patient
defin
fever
suspect
respiratori
infect
plu
one
respiratori
rate
breathsmin
sever
respiratori
distress
room
air
patient
pneumonia
sign
sever
pneumonia
defin
mild
case
sera
mild
patient
male
femal
averag
year
old
averag
day
ill
sera
sever
patient
male
femal
averag
year
old
averag
day
ill
assay
sera
healthi
peopl
physic
collect
clinic
laboratori
serum
level
detect
doubl
antibodi
sandwich
elisa
r
system
antibodi
therapi
mousehuman
chimer
antibodi
human
manufactur
cell
line
staidson
accord
good
manufactur
practic
cell
line
origin
develop
inflarx
gmbh
germani
licens
beij
deferengrei
biotech
co
ltd
wholli
own
subsidiari
staidson
biopharmaceut
co
ltd
inject
approv
nation
medic
product
administr
nmpa
china
phase
clinic
trial
healthi
subject
coronaviru
induc
pneumonia
outbreak
antibodi
approv
nmpa
phase
ii
clinic
trial
treatment
februari
administr
antibodi
human
also
approv
ethic
committe
wuhan
huoshenshan
hospit
mg
antibodi
ml
salin
administr
iv
day
arteri
blood
ga
abg
test
c
reaction
protein
crp
blood
routin
blood
rt
hepat
function
regularli
determin
blood
pressur
heart
beat
monitor
requir
data
present
mean
mean
analyz
use
twotail
student
test
anova
surviv
curv
analyz
logrank
test
gehanbreslowwilcoxon
test
parametr
regress
model
differ
consid
signific
p
p
p
indic
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
relat
concentr
n
protein
sarscov
merscov
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
fig
n
protein
potenti
lpsinduc
pneumonia
mice
balbc
mice
micegroup
infect
pfu
adsar
nadnul
salin
control
lp
mgkg
given
day
post
infect
dpi
antibodi
mgkg
inject
min
lp
inject
fatal
mice
note
b
lung
paraffin
section
analyz
stain
c
mice
infect
pfu
adsar
nadnul
lp
mgkg
given
dpi
mice
sacrif
lp
challeng
hr
frozen
lung
section
stain
antibodi
sarscov
n
complex
format
frozen
lung
section
measur
situ
pla
indic
red
signal
deposit
fragment
stain
fitclabel
antibodi
green
scale
bar
e
mice
preinfect
pfu
admer
nadnul
treat
lp
antibodi
mention
mice
surviv
curv
plot
f
mice
infect
nexpress
adenoviru
inject
lp
mention
mice
surviv
curv
plot
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
